Genetic Testing: Personalized Medicine at its Best

February 16, 2018

In 2013, the US Supreme Court ruled against one company owning the patent on genetic testing for BRCA1 and BRCA2 genes. Changes in these genes are associated with a high risk for breast cancer and ovarian cancer. The ruling cited that human genes are not eligible for patents because they are a product of nature. Since this ruling, the world of cancer genetic testing has opened up both scientifically and financially.

Read More Categories: Ovarian Cancer, Breast Cancer, Cancer Screening, Genetic Testing, Colon & Rectal Cancer